Search Results - "Papavassilis, Charis" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

by Mrowietz, Ulrich, MD, Leonardi, Craig L., MD, Girolomoni, Giampiero, MD, Toth, Darryl, MD, FRCPC, Morita, Akimichi, MD, Balki, Shyamal A., FCPS, Szepietowski, Jacek C., MD, Regnault, Pascaline, PhD, Thurston, Helen, MSc, Papavassilis, Charis, MD
Published in Journal of the American Academy of Dermatology (01.07.2015)

Get full text

Journal Article

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

by van de Kerkhof, Peter C.M., MD, PhD, Griffiths, Christopher E.M., MD, Reich, Kristian, MD, PhD, Leonardi, Craig L., MD, Blauvelt, Andrew, MD, MBA, Tsai, Tsen-Fang, MD, Gong, Yankun, PhD, Huang, Jiaqing, MD, PhD, Papavassilis, Charis, MD, PhD, Fox, Todd, RPh, PharmB, ACPR
Published in Journal of the American Academy of Dermatology (01.07.2016)

Get full text

Journal Article

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

by Gottlieb, Alice B, Deodhar, Atul, Mcinnes, Iain B, Baraliakos, Xenofon, Reich, Kristian, Schreiber, Stefan, Bao, Weibin, Marfo, Kwaku, Richards, Hanno B, Pricop, Luminita, Shete, Abhijit, Trivedi, Vivek, Keefe, Deborah, Papavassilis, Charis C, Jagiello, Piotr, Papanastasiou, Philemon, Mease, Philip J, Lebwohl, Mark
Published in Acta dermato-venereologica (27.04.2022)

Get full text

Journal Article

Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients

Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients

by Balp, Maria‐Magdalena, Weller, Karsten, Carboni, Veruska, Chirilov, Alexandra, Papavassilis, Charis, Severin, Thomas, Tian, Haijun, Zuberbier, Torsten, Maurer, Marcus
Published in Pediatric allergy and immunology (01.09.2018)

Get full text

Journal Article

Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study

Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study

by Ohtsuki, Mamitaro, Morita, Akimichi, Abe, Masatoshi, Takahashi, Hidetoshi, Seko, Noriko, Karpov, Alexander, Shima, Tomohiro, Papavassilis, Charis, Nakagawa, Hidemi
Published in Journal of dermatology (01.12.2014)

Get full text

Journal Article

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

by Langley, Richard G, Elewski, Boni E, Lebwohl, Mark, Reich, Kristian, Griffiths, Christopher E.M, Papp, Kim, Puig, Lluís, Nakagawa, Hidemi, Spelman, Lynda, Sigurgeirsson, Bárður, Rivas, Enrique, Tsai, Tsen-Fang, Wasel, Norman, Tyring, Stephen, Salko, Thomas, Hampele, Isabelle, Notter, Marianne, Karpov, Alexander, Helou, Silvia, Papavassilis, Charis
Published in The New England journal of medicine (24.07.2014)

Get full text

Journal Article

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept

by Strober, Bruce, MD, PhD, Gottlieb, Alice B., MD, PhD, Sherif, Bintu, MS, Mollon, Patrick, MD, MBA, MSc, Gilloteau, Isabelle, MSc, McLeod, Lori, PhD, Fox, Todd, PharmD, Mordin, Margaret, MS, Gnanasakthy, Ari, MSc, MBA, Papavassilis, Charis, MD, PhD, Lebwohl, Mark G., MD
Published in Journal of the American Academy of Dermatology (01.04.2017)

Get full text

Journal Article

Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials

Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials

by Strober, Bruce, Sigurgeirsson, Bárður, Popp, Georg, Sinclair, Rodney, Krell, James, Stonkus, Sigitas, Septe, Marcis, Elewski, Boni E., Gottlieb, Alice B., Zhao, Yang, Tran, Mary H., Karpov, Alexander, McLeod, Lori D., Mordin, Margaret, Papavassilis, Charis, Nyirady, Judit, Lebwohl, Mark
Published in International journal of dermatology (01.04.2016)

Get full text

Journal Article

Item-Level Psychometric Properties for a New Patient-Reported Psoriasis Symptom Diary

Item-Level Psychometric Properties for a New Patient-Reported Psoriasis Symptom Diary

by Strober, Bruce E., MD, PhD, Nyirady, Judit, MD, MBA, Mallya, Usha G., PhD, Guettner, Achim, PhD, Papavassilis, Charis, MD, PhD, Gottlieb, Alice B., MD, PhD, Elewski, Boni E., MD, Turner-Bowker, Diane M., PhD, Shields, Alan L., PhD, Gwaltney, Chad J., PhD, Lebwohl, Mark, MD
Published in Value in health (01.09.2013)

Get full text

Journal Article

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

by Körber, Andreas, Papavassilis, Charis, Bhosekar, Vaishali, Reinhardt, Maximilian
Published in Drugs & aging (01.02.2018)

Get full text

Journal Article

Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis

Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis

by Pinter, Andreas, Gerdes, Sascha, Papavassilis, Charis, Reinhardt, Maximilian
Published in The Journal of dermatological treatment (16.11.2020)

Get full text

Journal Article

The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials

The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials

by Langley, Richard G. B., Feldman, Steven R., Nyirady, Judit, van de Kerkhof, Peter, Papavassilis, Charis
Published in The Journal of dermatological treatment (01.02.2015)

Get full text

Journal Article

Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials

Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials

by Langley, Richard G, Sofen, Howard, Dei-Cas, Ignacio, Reich, Kristian, Sigurgeirsson, Bardur, Warren, Richard B, Paul, Carle, Szepietowski, Jacek C, Tsai, Tsen-Fang, Hampele, Isabelle, You, Ruquan, Charef, Pascal, Papavassilis, Charis
Published in British journal of dermatology (1951) (10.02.2023)

Get full text

Journal Article

25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year

by Bodemer, Christine, Kaszuba, Andrzej, Kingo, Külli, Tsianakas, Athanasios, Morita, Akimichi, Rivas, Enrique, Papanastasiou, Philemon, Patekar, Manmath, Papavassilis, Charis, Bruin, Gerard, You, Ruquan
Published in Journal of the American Academy of Dermatology (01.09.2021)

Get full text

Journal Article

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab

by Elewski, Boni E., Puig, Lluís, Mordin, Margaret, Gilloteau, Isabelle, Sherif, Bintu, Fox, Todd, Gnanasakthy, Ari, Papavassilis, Charis, Strober, Bruce E.
Published in The Journal of dermatological treatment (18.08.2017)

Get full text

Journal Article

Medium-chain triglycerides inhibit growth of Malassezia: implications for prevention of systemic infection

Medium-chain triglycerides inhibit growth of Malassezia: implications for prevention of systemic infection

by Papavassilis, C, Mach, K K, Mayser, P A
Published in Critical care medicine (01.09.1999)

Get more information

Journal Article

Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials

Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials

by Gottlieb, Alice B, Langley, Richard G, Philipp, Sandra, Sigurgeirsson, Bardur, Blauvelt, Andrew, Martin, Ruvie, Papavassilis, Charis, Mpofu, Shephard
Published in Journal of drugs in dermatology (01.08.2015)

Get more information

Journal Article

Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial

Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial

by Gottlieb, Alice B, Blauvelt, Andrew, Prinz, Jörg C, Papanastasiou, Philemon, Pathan, Rashidkhan, Nyirady, Judit, Fox, Todd, Papavassilis, Charis
Published in Journal of drugs in dermatology (01.10.2016)

Get more information

Journal Article

Reply to Ensina et al

Reply to Ensina et al

by Balp, Maria‐Magdalena, Weller, Karsten, Carboni, Veruska, Chirilov, Alexandra, Papavassilis, Charis, Severin, Thomas, Tian, Haijun, Zuberbier, Torsten, Maurer, Marcus
Published in Pediatric allergy and immunology (01.09.2018)

Get full text

Journal Article

Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results

Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results

by Langley, Richard G B, Reich, Kristian, Papavassilis, Charis, Fox, Todd, Gong, Yankun, Gu Ttner, Achim
Published in Journal of drugs in dermatology (01.08.2017)

Get more information

Journal Article